SATORI PHARMACEUTICALS Trademark

Trademark Overview

On Thursday, October 8, 2009, a trademark application was filed for SATORI PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the SATORI PHARMACEUTICALS trademark a serial number of 77844711. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, April 27, 2018. This trademark is owned by Satori Pharmaceuticals, Inc.. The SATORI PHARMACEUTICALS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

research and development in the field of neuroscience; research and development of therapies for the treatment of neurodegenerative disorders
satori pharmaceuticals

General Information

Serial Number77844711
Word MarkSATORI PHARMACEUTICALS
Filing DateThursday, October 8, 2009
Status710 - CANCELLED - SECTION 8
Status DateFriday, April 27, 2018
Registration Number4027455
Registration DateTuesday, September 20, 2011
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 5, 2011

Trademark Statements

Disclaimer with Predetermined Text"PHARMACEUTICALS"
Goods and Servicesresearch and development in the field of neuroscience; research and development of therapies for the treatment of neurodegenerative disorders

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, April 27, 2018
Primary Code042
First Use Anywhere DateMonday, May 31, 2004
First Use In Commerce DateMonday, May 31, 2004

Trademark Owner History

Party NameSatori Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameSatori Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameSatori Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Friday, April 27, 2018CANCELLED SEC. 8 (6-YR)
Tuesday, September 20, 2011EXPARTE APPEAL TERMINATED
Tuesday, September 20, 2011REGISTERED-PRINCIPAL REGISTER
Tuesday, July 5, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 5, 2011PUBLISHED FOR OPPOSITION
Thursday, June 2, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, May 27, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 13, 2011JURISDICTION RESTORED TO EXAMINING ATTORNEY
Monday, March 7, 2011NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Monday, March 7, 2011ACTION DENYING REQ FOR RECON E-MAILED
Monday, March 7, 2011ACTION CONTINUING FINAL - COMPLETED
Friday, February 25, 2011TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 25, 2011CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, February 14, 2011TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, February 14, 2011EX PARTE APPEAL-INSTITUTED
Monday, February 14, 2011JURISDICTION RESTORED TO EXAMINING ATTORNEY
Monday, February 14, 2011EXPARTE APPEAL RECEIVED AT TTAB
Friday, August 13, 2010NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, August 13, 2010FINAL REFUSAL E-MAILED
Friday, August 13, 2010FINAL REFUSAL WRITTEN
Friday, July 23, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 23, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 20, 2010ASSIGNED TO LIE
Thursday, July 8, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 8, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 8, 2010NON-FINAL ACTION E-MAILED
Friday, January 8, 2010NON-FINAL ACTION WRITTEN
Friday, January 8, 2010ASSIGNED TO EXAMINER
Thursday, October 15, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 12, 2009NEW APPLICATION ENTERED IN TRAM

Related Keywords

pharmaceuticals satori research development neurodegenerative disorders treatment neuroscience field therapies